Editas Medicine, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M | $90.7M | $20.5M | $31.9M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $90.0M | $199.2M | $177.7M | $175.0M | $142.5M | $158.0M | $96.9M | $90.7M |
| SG&A Expense | $49.9M | $72.0M | $69.7M | $70.7M | $76.2M | $67.6M | $64.6M | $55.0M |
| Operating Income | $-160.0M | $-251.2M | $-169.2M | $-226.0M | $-193.1M | $-134.8M | $-140.9M | $-113.7M |
| Operating Margin | -394.9% | -777.2% | -216.6% | -1,146.3% | -756.1% | -148.6% | -686.4% | -356.1% |
| Interest Expense | $6.2M | $2.2M | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | — | — | — |
| Net Income | $-160.1M | $-237.1M | $-153.2M | $-220.4M | $-192.5M | $-116.0M | $-133.7M | $-110.0M |
| Net Margin | -395.0% | -733.7% | -196.1% | -1,118.3% | -753.6% | -127.8% | -651.4% | -344.3% |
| EPS (Basic) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | $-2.33 |
| EPS (Diluted) | $-1.80 | $-2.88 | $-2.02 | $-3.21 | $-2.85 | $-1.98 | $-2.68 | $-2.33 |
| Shares Outstanding (Basic) | 88.7M | 82.3M | 76.0M | 68.7M | 67.6M | 58.6M | 50.0M | 48.8M |
| Shares Outstanding (Diluted) | 88.7M | 82.3M | 76.0M | 68.7M | 67.6M | 58.6M | 50.0M | 48.8M |
| Dividends Per Share | — | — | — | — | — | — | — | — |